A method of treating a chronic wound may comprise applying to the wound a first scaffold comprising an electrospun polymer fiber. The electrospun fiber may comprise a polymer selected from the group consisting of polyglycolic acid, poly(lactide-co-caprolactone), polylactic acid, polycaprolactone, copolymers thereof, and combinations thereof. The first scaffold may have a thickness from about 50 μm to about 1 mm, a length from about 1 cm to about 20 cm, and a width from about 1 cm to about 15 cm. The method may further comprise keeping the first scaffold on the chronic wound for a time period of about 3 days to about 21 days. After the time period passes, the chronic wound may have a decreased planimetric area.

A wound covering is provided that comprises a substrate and vitamin D, or analogues or metabolites thereof, embedded in the substrate. Methods of making a wound covering are also provided and include the steps of providing a solution that includes a polymer; adding vitamin D, or analogues or metabolites thereof, to the solution to form a mixture; and forming one or more fibers from the mixture that are then embedded with the vitamin D, or analogues or metabolites thereof. Methods of treating a subject are further provided and include the step of applying a wound covering including one or more fibers embedded with vitamin D, or analogues or metabolites thereof, to a site on a subject.

A wound covering is provided that comprises a substrate and vitamin D, or analogues or metabolites thereof, embedded in the substrate. Methods of making a wound covering are also provided and include the steps of providing a solution that includes a polymer; adding vitamin D, or analogues or metabolites thereof, to the solution to form a mixture; and forming one or more fibers from the mixture that are then embedded with the vitamin D, or analogues or metabolites thereof. Methods of treating a subject are further provided and include the step of applying a wound covering including one or more fibers embedded with vitamin D, or analogues or metabolites thereof, to a site on a subject.

The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.

The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.

Disclosed is an absorbent article with biocompostable properties, such as a baby diaper or adult incontinence product. Particularly, the present invention is directed to a biocompostable absorbent sanitary article including a blend of synthetic and bio-based superabsorbent polymers with a high degree of biocompostability. The sanitary article comprises, in one embodiment, at least a top layer, a back layer, and absorbent core, wherein the absorbent core includes a superabsorbent polymer, and wherein at least the superabsorbent polymer is biocompostable.

A block copolymer (A) including a vinyl alcohol-based polymer block (b) and an ionic polymer block (c) containing a monomer unit with an ionic group forming a salt and a vinyl alcohol-based monomer unit. The ionic group is a carboxylic acid group, a sulfonic acid group, or an ammonium group. The vinyl alcohol-based polymer block (b) has a number-average molecular weight (Mn.sub.b) from 15,000 to 220,000. The ionic polymer block (c) has a content of the vinyl alcohol-based monomer unit from 5 to 95 mol % based on the total monomer units. The block copolymer (A) has a number-average molecular weight (Mn.sub.A) from 20,000 to 440,000. A ratio (Mn.sub.b/Mn.sub.A) of the number-average molecular weight (Mn.sub.b) to the number-average molecular weight (Mn.sub.A) is from 0.1 to 0.9.

Described herewith are compositions comprising placental growth factors and methods for non-surgical, localized delivery thereof. The composition is delivered to a diseased or injured organ and/or body part and is formulated in a manner which allows for localized retention of the composition at the site of delivery.

Described herewith are compositions comprising placental growth factors and methods for non-surgical, localized delivery thereof. The composition is delivered to a diseased or injured organ and/or body part and is formulated in a manner which allows for localized retention of the composition at the site of delivery.

Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients).